165 related articles for article (PubMed ID: 38609396)
1. Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.
Song GY; Kim HJ; Kim T; Ahn SY; Jung SH; Kim M; Yang DH; Lee JJ; Kim MY; Cheong JW; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Park SK; Kim SH; Choi CK; Kim HJ; Ahn JS; Kim DDH
Sci Rep; 2024 Apr; 14(1):8517. PubMed ID: 38609396
[TBL] [Abstract][Full Text] [Related]
2. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Hansen DK; Kim J; Thompson Z; Hussaini M; Nishihori T; Ahmad A; Elmariah H; Faramand R; Mishra A; Davila ML; Khimani F; Lazaryan A; Sallman D; Liu H; Perez LE; Fernandez H; Nieder ML; Lancet JE; Pidala JA; Anasetti C; Bejanyan N
Transplant Cell Ther; 2021 Mar; 27(3):256.e1-256.e7. PubMed ID: 33781526
[TBL] [Abstract][Full Text] [Related]
3. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
[TBL] [Abstract][Full Text] [Related]
4. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
Oran B; Jimenez AM; De Lima M; Popat UR; Bassett R; Andersson B; Borthakur G; Bashir Q; Chen J; Ciurea SO; Jabbour E; Cortes J; Kebriaei P; Khouri IF; Qazilbash MH; Ravandi F; Rondon G; Lu X; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1405-1412. PubMed ID: 25840338
[TBL] [Abstract][Full Text] [Related]
5. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Bataller A; Garrido A; Guijarro F; Oñate G; Diaz-Beyá M; Arnan M; Tormo M; Vives S; de Llano MPQ; Coll R; Gallardo D; Vall-Llovera F; Escoda L; Garcia-Guiñon A; Salamero O; Sampol A; Merchan BM; Bargay J; Castaño-Díez S; Esteban D; Oliver-Caldés A; Rivero A; Mozas P; López-Guerra M; Pratcorona M; Zamora L; Costa D; Rozman M; Nomdedéu JF; Colomer D; Brunet S; Sierra J; Esteve J
Blood Adv; 2022 Feb; 6(4):1193-1206. PubMed ID: 34911079
[TBL] [Abstract][Full Text] [Related]
6. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
[TBL] [Abstract][Full Text] [Related]
7. Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine.
Kim M; Ahn SY; Kim T; Jung SH; Song GY; Yang DH; Lee JJ; Kim MY; Park JH; Shin MG; Ahn JS; Kim HJ; Kim DDH
Hematology; 2024 Dec; 29(1):2324417. PubMed ID: 38433437
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients.
Tsai CH; Yao CY; Tien FM; Tang JL; Kuo YY; Chiu YC; Lin CC; Tseng MH; Peng YL; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
EBioMedicine; 2019 Feb; 40():240-250. PubMed ID: 30662003
[TBL] [Abstract][Full Text] [Related]
9. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Rausch C; Rothenberg-Thurley M; Dufour A; Schneider S; Gittinger H; Sauerland C; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; von Bergwelt-Baildon M; Spiekermann K; Herold T; Metzeler KH
Leukemia; 2023 Jun; 37(6):1234-1244. PubMed ID: 37041198
[TBL] [Abstract][Full Text] [Related]
10. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Herold T; Rothenberg-Thurley M; Grunwald VV; Janke H; Goerlich D; Sauerland MC; Konstandin NP; Dufour A; Schneider S; Neusser M; Ksienzyk B; Greif PA; Subklewe M; Faldum A; Bohlander SK; Braess J; Wörmann B; Krug U; Berdel WE; Hiddemann W; Spiekermann K; Metzeler KH
Leukemia; 2020 Dec; 34(12):3161-3172. PubMed ID: 32231256
[TBL] [Abstract][Full Text] [Related]
11. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.
Jentzsch M; Grimm J; Bill M; Brauer D; Backhaus D; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Bone Marrow Transplant; 2021 Apr; 56(4):936-945. PubMed ID: 33208914
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
Mrózek K; Marcucci G; Nicolet D; Maharry KS; Becker H; Whitman SP; Metzeler KH; Schwind S; Wu YZ; Kohlschmidt J; Pettenati MJ; Heerema NA; Block AW; Patil SR; Baer MR; Kolitz JE; Moore JO; Carroll AJ; Stone RM; Larson RA; Bloomfield CD
J Clin Oncol; 2012 Dec; 30(36):4515-23. PubMed ID: 22987078
[TBL] [Abstract][Full Text] [Related]
13. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Döhner K; Thiede C; Jahn N; Panina E; Gambietz A; Larson RA; Prior TW; Marcucci G; Jones D; Krauter J; Heuser M; Voso MT; Ottone T; Nomdedeu JF; Mandrekar SJ; Klisovic RB; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Jansen JH; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Benner A; Pallaud C; Stone RM; Döhner H; Bloomfield CD
Blood; 2020 Jan; 135(5):371-380. PubMed ID: 31826241
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system.
Zhang H; Zheng X; Guo W; Xia Y; Zhang R; Zhai W; Chen X; Ma Q; Yang D; Wei J; Pang A; He Y; Feng S; Wang J; Han M; Jiang E
Exp Hematol Oncol; 2024 Feb; 13(1):16. PubMed ID: 38360825
[TBL] [Abstract][Full Text] [Related]
15. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.
Lachowiez CA; Long N; Saultz J; Gandhi A; Newell LF; Hayes-Lattin B; Maziarz RT; Leonard J; Bottomly D; McWeeney S; Dunlap J; Press R; Meyers G; Swords R; Cook RJ; Tyner JW; Druker BJ; Traer E
Blood Adv; 2023 May; 7(9):1899-1909. PubMed ID: 36441905
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.
Harada Y; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kobayashi S; Kitamura K; Sakaida E; Onizuka M; Takeshita A; Ishida F; Suzushima H; Ishizawa K; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Leuk Res; 2018 Mar; 66():20-27. PubMed ID: 29360622
[TBL] [Abstract][Full Text] [Related]
17. Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.
Hemmati PG; Vuong LG; Terwey TH; Jehn CF; le Coutre P; Penack O; Na IK; Dörken B; Arnold R
Eur J Haematol; 2017 Feb; 98(2):160-168. PubMed ID: 27706846
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation.
Grimm J; Jentzsch M; Bill M; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Blood Adv; 2020 Aug; 4(16):3864-3874. PubMed ID: 32810221
[TBL] [Abstract][Full Text] [Related]
19. [AML treatment strategy based on cytogenetic abnormalities and somatic mutations].
Imai Y
Rinsho Ketsueki; 2015 Oct; 56(10):1932-41. PubMed ID: 26458431
[TBL] [Abstract][Full Text] [Related]
20. Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
Mohty R; Massoud R; Chakhachiro Z; Mahfouz R; Nassif S; El-Cheikh J; Bazarbachi A; Abou Dalle I
Leuk Res; 2021 Jun; 105():106568. PubMed ID: 33857784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
